Inotiv Leverages LifeNet Health Proprietary Platform to Advance New Approach Methodologies in Translational Drug Discovery

Inotiv (NASDAQ: NOTV) announced on January 13, 2026 a strategic initiative to integrate LifeNet Health’s patented TruVivo® platform into its Discovery and Translational Sciences (DTS) business.

Rhea-AI Summary

Inotiv (NASDAQ: NOTV) announced on January 13, 2026 a strategic initiative to integrate LifeNet Health’s patented TruVivo® platform into its Discovery and Translational Sciences (DTS) business.

The TruVivo® system uses primary human hepatocytes with human-derived feeder cells to build physiologically relevant in vitro models intended to improve translational predictivity. Inotiv said the integration will align preclinical models more closely with human biology and enable expansion of human-relevant tissue models beyond the liver to support clients across a range of diseases.

The companies framed the collaboration as advancing new approach methodologies to accelerate development of safer, more effective therapies.

Argus Jan 13 session

-3.25% close to close Open Argus

Details

News Market Reaction – NOTV

On Jan 13, the day this news came out, NOTV closed 3.25% below the previous close.

Data tracked by StockTitan Argus for the Jan 13 session.

Historical Context

5 past events · Latest: Dec 11

5 events

1. Dec 11

   AI partnership

   24h Move

   -4.5%

   AI/ML bioinformatics collaboration to enhance drug discovery capabilities.

2. Dec 03

   Earnings update

   24h Move

   +8.1%

   Q4 and FY2025 results with revenue growth and narrowed operating loss.

3. Nov 25

   Growth ranking

   24h Move

   +3.9%

   Deloitte Fast 500 ranking highlighting multi-year revenue growth.

4. Nov 21

   Earnings date notice

   24h Move

   -3.9%

   Announcement of timing for Q4/FY2025 earnings release and call.

5. Nov 17

   Prelim results

   24h Move

   -33.2%

   Preliminary FY2025 revenue and strong DSA growth ahead of audit.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

hepatocytes, in vitro, preclinical, translational science

4 terms

hepatocytes medical

"uses primary human hepatocytes cultured with human-derived feeder cells"

Hepatocytes are the main functional cells of the liver that act like factory workers, breaking down nutrients, producing important proteins, making bile to aid digestion, and clearing toxins and drugs from the blood. For investors, hepatocyte health and behavior matter because they determine liver function, influence drug safety and dosing, affect outcomes in liver disease markets, and play a central role in regulatory drug testing and approval.

in vitro medical

"to create physiologically relevant in vitro models"

In vitro describes laboratory tests performed on cells, tissues, or biological molecules outside a living body—literally “in glass,” such as in test tubes or dishes. For investors, in vitro results are an early sign that a drug or technology has a desired effect under controlled conditions, but they don’t guarantee it will work or be safe in animals or people; think of them as a prototype tested on a bench rather than in real-world use.

preclinical medical

"transforming preclinical research through human-relevant technologies"

Preclinical describes the stage of drug or medical-product development when researchers test a candidate in the lab and in animals to see if it is safe, reaches intended targets, and shows basic effectiveness before any human trials begin. For investors, preclinical status signals an early, higher‑risk opportunity where positive lab results can increase value but significant work, time, and regulatory hurdles remain — like proofing a prototype in a workshop before road testing.

translational science medical

"“Translational science is about connecting basic research to patient outcomes,”"

Translational science is the process of turning laboratory discoveries into practical medical tests, therapies, or devices and figuring out how to deliver them safely to patients. For investors, it matters because progress in this area signals a clearer path from research to sellable products—like converting a prototype into a finished product—affecting a company’s potential revenue, regulatory risk, and likelihood of partnerships or buyouts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WEST LAFAYETTE, Ind., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced a strategic initiative to leverage LifeNet Health’s proprietary TruVivo^® within its Discovery and Translational Sciences business.

LifeNet Health, a global leader in regenerative medicine, has developed the patented TruVivo^® system, which uses primary human hepatocytes cultured with human-derived feeder cells to create physiologically relevant in vitro models. This technology provides a stronger foundation for predicting human responses to new therapies and addresses a critical challenge in drug development.

“Translational science is about connecting basic research to patient outcomes,” said Scott Daniels, PhD, Senior Vice President of Discovery & Translational Sciences (DTS) at Inotiv. “Integrating the TruVivo^® platform into our disease pharmacology offering allows us to better align preclinical models with human biology. The versatility of LifeNet Health’s platform will also enable us to extend human-relevant tissue models beyond the liver, advancing innovation for clients addressing a wide range of human diseases.”

“Our mission is to Save Lives, Restore Health and Give Hope by accelerating scientific innovation that translates into meaningful human impact,” said Susan Campbell, General Manager LifeSciences at LifeNet Health, “and this collaboration underscores our shared vision of transforming preclinical research through human-relevant technologies.”

By leveraging LifeNet Health’s proprietary platform, Inotiv strengthens its commitment to new approach methodologies that advance human-relevant science, improve translational predictivity, and accelerate the development of safer, more effective therapies for patients.

About Inotiv
Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs and medical devices to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical research and development projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: https://www.inotiv.com/.

About LifeNet Health LifeSciences
LifeNet Health LifeSciences delivers human-based research solutions that accelerate discovery and improve patient safety. As part of LifeNet Health, a nonprofit organization dedicated for over 40 years to saving lives, we bridge donation and science with unmatched human relevance. Our portfolio includes characterized liver cells and tissues, prospective biospecimen recovery, and advanced in vitro systems, empowering researchers worldwide to develop safer, more effective therapies. To learn more, visit: https://lnhlifesciences.org.

This release contains "forward-looking statements," within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are generally identified with words such as “aim”, “anticipate”, “assume”, “believe”, “could”, “estimate”, “expect”, “future”, “goal”, “intend”, “likely”, “may”, “plan”, “project”, “seek”, “strategy”, “target”, “will” and similar expressions. Forward-looking statements in this release include, but are not limited to, statements regarding the Company’s new strategic collaboration, including the workings of the collaboration and its expected effects, impacts and results, potential expansions and additional innovation, and commitments to new approach methodologies and their expected effects, impacts and results. These forward-looking statements are not statements of historical facts and represent only the Company’s current expectations regarding such matters. All forward-looking statements are subject to significant risks, uncertainties and changes in circumstances that could cause actual results and outcomes to differ materially from those expressed or implied in the forward-looking statements, including, but are not limited to, those detailed in the Company's filings with the U.S. Securities and Exchange Commission. Further discussion of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in the Company’s Annual Report on Form 10-K as filed on December 5, 2025, as well as other filings with the Securities and Exchange Commission. Except to the extent required by law, the Company does not undertake, and expressly disclaims, any duty or obligation to update publicly any forward-looking statement after the date of this release, whether as a result of new information, future events, changes in assumptions or otherwise.

Inotiv Company Contact		Inotiv Investor Relations
Inotiv, Inc.		LifeSci Advisors
Beth A. Taylor, Chief Financial Officer		Steve Halper
(765) 497-8381		(646) 876-6455
beth.taylor@inotiv.com		shalper@lifesciadvisors.com
LifeNet Health Media Contact
stratcomm@lifenethealth.org

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Inotiv (NOTV) announce on January 13, 2026 about LifeNet Health?

Inotiv announced a strategic initiative to integrate LifeNet Health’s patented TruVivo® platform into its Discovery and Translational Sciences business.

How does the TruVivo® platform used by NOTV work and what models does it target?

TruVivo® uses primary human hepatocytes cultured with human-derived feeder cells to create physiologically relevant in vitro models, initially focused on liver and extensible to other tissues.

What is the stated goal of Inotiv’s integration of LifeNet Health technology?

The goal is to improve translational predictivity by aligning preclinical models with human biology and to accelerate development of safer, more effective therapies.

Which Inotiv business unit will leverage LifeNet Health’s TruVivo® system?

The Discovery and Translational Sciences (DTS) business will leverage the TruVivo® platform.

Will the TruVivo® integration expand beyond liver models according to Inotiv (NOTV)?

Yes; Inotiv said the platform’s versatility will enable extending human-relevant tissue models beyond the liver to address a wide range of diseases.

Does the announcement include financial guidance or transaction terms for NOTV?

No; the announcement describes a strategic initiative and scientific collaboration but does not disclose financial terms or guidance.